Ligand Pharmaceuticals (LGNYZ) EBT Margin (2016 - 2025)
Historic EBT Margin for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to 122.24%.
- Ligand Pharmaceuticals' EBT Margin rose 1344700.0% to 122.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 25.07%, marking a year-over-year decrease of 135200.0%. This contributed to the annual value of 1.51% for FY2024, which is 469700.0% down from last year.
- As of Q3 2025, Ligand Pharmaceuticals' EBT Margin stood at 122.24%, which was up 1344700.0% from 23.56% recorded in Q2 2025.
- Over the past 5 years, Ligand Pharmaceuticals' EBT Margin peaked at 366.22% during Q1 2024, and registered a low of 157.45% during Q2 2024.
- For the 5-year period, Ligand Pharmaceuticals' EBT Margin averaged around 25.01%, with its median value being 20.86% (2022).
- Per our database at Business Quant, Ligand Pharmaceuticals' EBT Margin soared by 2399400bps in 2024 and then tumbled by -4769100bps in 2025.
- Over the past 5 years, Ligand Pharmaceuticals' EBT Margin (Quarter) stood at 31.7% in 2021, then soared by 51bps to 47.91% in 2022, then grew by 27bps to 60.84% in 2023, then plummeted by -250bps to 91.56% in 2024, then soared by 234bps to 122.24% in 2025.
- Its EBT Margin stands at 122.24% for Q3 2025, versus 23.56% for Q2 2025 and 110.69% for Q1 2025.